Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aseem Anand

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|August 31, 2021
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [<sup>18</sup>F]DCFPyL (PSMA) imaging for standardized reportingKerstin Johnsson, Johan Brynolfsson, Hannicka Sahlstedt, et al.
The Prostate|May 3, 2019
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancerMegan Ann McNamara, Taofik Oyekunle, Bennett B Chin, et al.
BJU International|July 24, 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic diseaseMichael J Donovan, Iman Osman, Faisal M Khan, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2010
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancerDana Rathkopf, Bryan Y Wong, Robert W Ross, et al.
European Urology|August 20, 2013
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survivalDaniel C Danila, Aseem Anand, Nikolaus Schultz, et al.
EJNMMI Research|March 11, 2016
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamideAseem Anand, Michael J Morris, Steven M Larson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancerMargaret A Leversha, Jialian Han, Zahra Asgari, et al.
Oncotarget|December 13, 2017
Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasisEmelie Englund, Giacomo Canesin, Konstantinos S Papadakos, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
European Journal of Nuclear Medicine and Molecular Imaging|August 31, 2021
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [<sup>18</sup>F]DCFPyL (PSMA) imaging for standardized reportingKerstin Johnsson, Johan Brynolfsson, Hannicka Sahlstedt, et al.
The Prostate|May 3, 2019
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancerMegan Ann McNamara, Taofik Oyekunle, Bennett B Chin, et al.
BJU International|July 24, 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic diseaseMichael J Donovan, Iman Osman, Faisal M Khan, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2010
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancerDana Rathkopf, Bryan Y Wong, Robert W Ross, et al.
European Urology|August 20, 2013
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survivalDaniel C Danila, Aseem Anand, Nikolaus Schultz, et al.
EJNMMI Research|March 11, 2016
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamideAseem Anand, Michael J Morris, Steven M Larson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancerMargaret A Leversha, Jialian Han, Zahra Asgari, et al.
Oncotarget|December 13, 2017
Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasisEmelie Englund, Giacomo Canesin, Konstantinos S Papadakos, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Pageof 4